Owlstone Medical collaborates with Thermo Fisher Scientific to advance use of breath samples to detect disease

Cambridge: Owlstone Medical, recently announced it has partnered with Thermo Fisher Scientific. The collaboration seeks to advance the application of non-invasive breath sampling to address the challenges of the early detection of disease and the precision medicine delivery of healthcare through the discovery and validation of novel biomarkers.

Under the agreement, both parties will work to integrate the Thermo Scientific Q Exactive GC Hybrid Quadrupole-Orbitrap Mass Spectrometer into Owlstone Medical’s Breath Biopsy platform. An initial project will seek to qualify the mass analyzer for the detection of new biomarkers via a validated discovery and routine analysis project. Upon successful completion, the technology will then become a standard part of Owlstone Medical’s biomarker discovery process, whereby metabolomic studies are conducted on breath samples for internal programs, or on behalf of pharmaceutical or academic clients, to discover novel biomarkers that could translate into research and clinical tests. The work will take place at Owlstone Medical’s Cambridge, UK, Breath Biopsy laboratory.

Breath Biopsy represents an entirely new way to measure the chemical makeup of breath by measuring volatile organic compounds (VOCs), which are gaseous molecules that can be sampled quickly and non-invasively from breath and enabling whole-body sampling. These compounds are produced as the end product of metabolic processes within the body, meaning underlying changes in metabolic activity can produce particular patterns of VOCs characteristic of specific diseases.

VOCs originating from all parts of the body are captured in breath making Breath Biopsy applicable to a wide range of diseases including cancer, inflammatory disease, infectious disease, metabolic disease, cardiovascular disease and respiratory disease. The nature of Breath Biopsy and VOC biomarkers make them perfectly suited to addressing two of the major challenges of healthcare today: early detection and precision medicine.

Breath collection is carried out using Owlstone Medical’s ReCIVA Breath Sampler, which ensures reliable, reproducible collection of VOCs. Subjects breathe a controlled supply of air, and samples of their exhaled breath are captured and stabilized on Breath Biopsy Cartridges, which can then be shipped for analysis with Owlstone Medical’s Breath Biopsy analytical platform, using mass spectrometry or FAIMS to determine their VOC profile. Advanced data analytic techniques can then be applied in order to pinpoint the VOCs of interest.

Commenting on the same, Morten Bern, senior director marketing, chromatography and mass spectrometry, Thermo Fisher Scientific said, “There is clearly a growing need for non-invasive diagnostic solutions to support the early detection of disease.”

“The integration of our Orbitrap GC-MS technology with Owlstone Medical’s Breath Biopsy platform provides a unique basis to improve patient outcomes through the discovery of breath biomarkers and their incorporation into clinical practice, ” Bern added.

Read Also: Thermo Fisher, NX Prenatal collaborates to advance noninvasive risk assessments of pregnancy outcomes

Billy Boyle, co-founder and CEO at Owlstone Medical, said, “The GC Orbitrap platform’s ability to detect a wide range of chemicals during both targeted and untargeted analyses without losing selectivity or sensitivity, promises to be of substantial benefit to our Breath Biopsy platform. With a large and rapidly expanding installed base of GC Orbitrap systems, our partnership with Thermo Fisher Scientific represents an exciting opportunity for cross-promotion of the platform and technique, by which the benefits of Breath Biopsy can be broadly realized.”

Further to the scientific and technical expertise, this collaboration will be supported by a joint marketing and customer support effort to ensure the global reach of the Breath Biopsy platform.

Read Also: Thermo Fisher to acquire Brammer Bio in 1.7 Billion Dollar deal